Literature DB >> 23180957

Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia.

Siham Al Sinani1, Yusria Al Rawahi, Hamed Abdoon.   

Abstract

A number of disorders have been described to cause protein losing enteropathy (PLE) in children. Primary intestinal lymphangiectasia (PIL) is one mechanism leading to PLE. Few syndromes are associated with PIL; Hennekam syndrome (HS) is one of them. The principal treatment for PIL is a high protein, low fat diet with medium chain triglycerides supplementation. Supportive therapy includes albumin infusion. Few publications have supported the use of octreotide to diminish protein loss and minimize hypoalbuminemia seen in PIL. There are no publications on the treatment of PIL with octreotide in patients with HS. We report two children with HS and PLE in which we used octreotide to decrease intestinal protein loss. In one patient, octreotide increased serum albumin to an acceptable level without further need for albumin infusions. The other patient responded more dramatically with near normal serum albumin levels and cessation of albumin infusions. In achieving a good response to octreotide in both patients, we add to the publications supporting the use of octreotide in PIL and suggest that octreotide should be tried in patients with PIL secondary to HS. To the best of our knowledge, this is the first case report on the use of octreotide in HS-associated PIL.

Entities:  

Keywords:  Hennekam syndrome; Lymphangiectasia; Octreotide; Protein losing enteropathy

Mesh:

Substances:

Year:  2012        PMID: 23180957      PMCID: PMC3501785          DOI: 10.3748/wjg.v18.i43.6333

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Use of a long acting somatostatin analogue in controlling ileostomy diarrhoea in infants.

Authors:  T Lamireau; R I Galpérine; P Ohlbaum; J L Demarquez; P Vergnes; Y Kurzenne; J P Hehunstre
Journal:  Acta Paediatr Scand       Date:  1990 Aug-Sep

2.  Watery diarrhea, hypokalemia, achlorhydria syndrome in an infant: effect of the long-acting somatostatin analogue SMS 201-995 on the disease and linear growth.

Authors:  S S Smith; D I Shulman; T M O'Dorisio; D T McClenathan; J A Borger; B B Bercu; A W Root
Journal:  J Pediatr Gastroenterol Nutr       Date:  1987 Sep-Oct       Impact factor: 2.839

3.  Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.

Authors:  V Gebbia; I Carreca; A Testa; R Valenza; G Curto; G Cannata; N Borsellino; M A Latteri; C Cipolla; M Florena
Journal:  Anticancer Drugs       Date:  1993-08       Impact factor: 2.248

4.  Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease.

Authors:  P Ely; J Dunitz; J Rogosheske; D Weisdorf
Journal:  Am J Med       Date:  1991-06       Impact factor: 4.965

5.  Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.

Authors:  Vinita Pai; Kyle Porter; Mark Ranalli
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

Review 6.  Clinical use of the long acting somatostatin analogue octreotide in pediatrics.

Authors:  M T Tauber; A G Harris; P Rochiccioli
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

7.  Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy.

Authors:  B Glaser; H J Hirsch; H Landau
Journal:  J Pediatr       Date:  1993-10       Impact factor: 4.406

8.  Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.

Authors:  S Cascinu; A Fedeli; S L Fedeli; G Catalano
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

9.  Clinical response to the long acting somatostatin analogue SMS 201-995 in a child with congenital microvillus atrophy.

Authors:  R T Couper; A Berzen; G Berall; P M Sherman
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

10.  Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation.

Authors:  R C Hennekam; R A Geerdink; B C Hamel; F A Hennekam; P Kraus; J A Rammeloo; A A Tillemans
Journal:  Am J Med Genet       Date:  1989-12
View more
  8 in total

1.  How to treat an extensive form of primary intestinal lymphangiectasia?

Authors:  Rosana Troskot; Dragan Jurčić; Ante Bilić; Marija Gomerčić Palčić; Stanko Težak; Ivana Brajković
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 2.  Primary intestinal lymphangiectasia: Minireview.

Authors:  Sachin B Ingle; Chitra R Hinge Ingle
Journal:  World J Clin Cases       Date:  2014-10-16       Impact factor: 1.337

3.  Hennekam Syndrome: A Case Report.

Authors:  Yeong Guk Lee; Seung Chan Kim; Si-Bog Park; Mi Jung Kim
Journal:  Ann Rehabil Med       Date:  2018-02-28

4.  Octreotide Use in Neonates: A Case Series.

Authors:  Syed Ahmed Zaki; Mohan B Krishnamurthy; Atul Malhotra
Journal:  Drugs R D       Date:  2018-09

Review 5.  Comparative pathophysiology and management of protein-losing enteropathy.

Authors:  Melanie D Craven; Robert J Washabau
Journal:  J Vet Intern Med       Date:  2019-02-14       Impact factor: 3.333

Review 6.  Etiology and Management of Pediatric Intestinal Failure: Focus on the Non-Digestive Causes.

Authors:  Antonella Diamanti; Giacomo Calvitti; Diego Martinelli; Emma Santariga; Teresa Capriati; Giulia Bolasco; Lorenzo Iughetti; Arturo Pujia; Daniela Knafelz; Giuseppe Maggiore
Journal:  Nutrients       Date:  2021-02-27       Impact factor: 5.717

Review 7.  Intestinal Lymphangiectasia: Insights on Management and Literature Review.

Authors:  Mohamad J Alshikho; Joud M Talas; Salem I Noureldine; Saf Zazou; Aladdin Addas; Haitham Kurabi; Mahmoud Nasser
Journal:  Am J Case Rep       Date:  2016-07-21

Review 8.  Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.

Authors:  Hans-Hartmut Peter; Hans D Ochs; Charlotte Cunningham-Rundles; Donald C Vinh; Peter Kiessling; Bernhard Greve; Stephen Jolles
Journal:  J Allergy Clin Immunol       Date:  2020-09       Impact factor: 10.793

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.